We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

159 hedge funds and large institutions have $612M invested in Progenics Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 16

69% more call options, than puts

Call options by funds: $6.1M | Put options by funds: $3.62M

26% more funds holding

Funds holding: 126 → 159 (+33)

25% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 36

18% more capital invested

Capital invested by funds: $518M → $612M (+$93.5M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
159
Holders Change
+33
Holders Change %
+26.19%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
56
Increased
45
Reduced
36
Closed
16
Calls
$6.1M
Puts
$3.62M
Net Calls
+$2.48M
Net Calls Change
+$1.34M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$95M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
3
PWAM
Park West Asset Management
California
+$12.6M
4
Invesco
Invesco
Georgia
+$10.3M
5
Goldman Sachs
Goldman Sachs
New York
+$5.62M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$69.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.91M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$2.13M
4
RA
Royce & Associates
New York
-$2.08M
5
PFC
Phocas Financial Corp
California
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
101
Matarin Capital Management
New York
$238K +$252K +25,228 New
TRSOTSOK
102
Teachers Retirement System of the State of Kentucky
Kentucky
$227K +$240K +24,000 New
ASN
103
Advisory Services Network
Georgia
$215K +$228K +22,825 New
T. Rowe Price Associates
104
T. Rowe Price Associates
Maryland
$213K – – –
DCM
105
Driehaus Capital Management
Illinois
$201K +$213K +21,323 New
FRM
106
Fox Run Management
Connecticut
$184K +$76.2K +7,632 +64%
QT
107
Quantbot Technologies
New York
$175K +$186K +18,610 New
MSA
108
Mason Street Advisors
Wisconsin
$155K +$163K +16,380 New
MAM
109
Morse Asset Management
Connecticut
$155K +$164K +16,400 New
MERSOM
110
Municipal Employees' Retirement System of Michigan
Michigan
$151K +$159K +15,960 New
ARTA
111
A.R.T. Advisors
New York
$147K +$156K +15,600 New
DSC
112
Duncker Streett & Co
Missouri
$139K – – –
JMPWA
113
JP Morgan Private Wealth Advisors
California
$138K +$145K +14,572 New
LPL Financial
114
LPL Financial
California
$133K -$3.57K -358 -2%
PA
115
Profund Advisors
Maryland
$128K +$135K +13,535 New
BNP Paribas Financial Markets
116
BNP Paribas Financial Markets
France
$122K +$118K +11,860 +1,077%
Creative Planning
117
Creative Planning
Kansas
$116K -$29.4K -2,950 -19%
UBS Group
118
UBS Group
Switzerland
$113K -$313K -31,387 -72%
WMC
119
Westwood Management Corporation
Illinois
$113K – – –
Tudor Investment Corp
120
Tudor Investment Corp
Connecticut
$95K +$58.9K +5,900 +140%
DekaBank Deutsche Girozentrale
121
DekaBank Deutsche Girozentrale
Germany
$86K -$9.98K -1,000 -10%
PI
122
PineBridge Investments
New York
$86K +$91.2K +9,137 New
PAM
123
Paradigm Asset Management
New York
$85.9K +$90.8K +9,100 New
LTFS
124
Ladenburg Thalmann Financial Services
Florida
$83K – – –
SOADOR
125
State of Alaska Department of Revenue
Alaska
$73K +$77.6K +7,770 New
3 4
5
6 7

PGNX Hedge Fund Activity: Q1 2017 in Review

159 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2017, worth a combined $612M — up 18% from $518M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new PGNX positions and 16 closed out — a net gain of 40 holders — while 45 added to existing stakes and 36 trimmed.

The largest buyer was BlackRock, adding an estimated $95M. The largest seller was Broadfin Capital, cutting an estimated $69.4M.

  • 159 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2017, up from 126 in Q4 2016.
  • Funds reported $612M of Progenics Pharmaceuticals Inc stock for Q1 2017, up 18% quarter-over-quarter.
  • 56 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2017 and 16 closed out, a net change of +40 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $95M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q1 2017 was Broadfin Capital, an estimated $69.4M sold.

Based on aggregated 13F filings for Q1 2017.